Enantioselective Assays in Comparative Bioavailability Studies of Racemic Drug Formulations: Nice to Know or Need to Know?
Author:
- 1 June 1996
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (6) , 490-499
Abstract
The importance of enantiospecific assays in studying pharmacokinetic/pharmacodynamic (PK/PD) and drug‐drug interactions of racemic drugs is widely recognized. Use of such assays in comparative bioavailability studies, however, remains controversial. This commentary proposes a PK/PD‐based rationale for deciding whether an enantioselective assay is important in such studies. Racemic drugs are divided into three major categories: those with negligible or nonenantioselective first‐pass metabolism (category I), those where the first‐pass metabolism of the less‐active enantiomer is predominant (category II), and those where the first‐pass metabolism of the more active and/or toxic enantiomer is predominant (category III). In addressing the need for assay selectivity, a simple analogy is made between these drug categories and the protein‐binding phenomenon. Enantioselective assays are not essential for category I drugs, or for category II drugs in the majority of cases. A special consideration, however, is needed for those category II drugs that undergo racemic inversion that may be influenced by the dose level and/or the residence time of the drug formulation in the gastrointestinal tract. It is with category III drugs that enantioselective assays become important, especially when metabolism, distribution, and/or elimination processes of the active or toxic enantiomer are saturable, leading to variable enantiomeric ratios in the plasma. Factors contributing to these ratio changes include routes of administration, dose level, and input rate differences. Input rate differences are particularly relevant to bioavailability evaluation of category III drugs.Keywords
This publication has 63 references indexed in Scilit:
- The Effect of Dosage Release Formulations on the Pharmacokinetics of Propranolol Stereoisomers in HumansThe Journal of Clinical Pharmacology, 1995
- Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studiesJournal of Pharmaceutical and Biomedical Analysis, 1994
- Chirality in New Drug DevelopmentClinical Pharmacokinetics, 1994
- Bioequivalence of Racemic DrugsThe Journal of Clinical Pharmacology, 1992
- Regulatory Requirements for Generic Chiral DrugsThe Journal of Clinical Pharmacology, 1992
- Stereoselective Disposition of Etodolac Enantiomers in Synovial FluidThe Journal of Clinical Pharmacology, 1991
- Nonlinear PharmacokineticsClinical Pharmacokinetics, 1991
- Clinical Pharmacokinetics of Ketoprofen and Its EnantiomersClinical Pharmacokinetics, 1990
- ChiralityClinical Pharmacokinetics, 1990
- The Importance of Stereochemistry in the Clinical Pharmacokinetics of the 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory DrugsClinical Pharmacokinetics, 1984